- Home
- LSF vs IFRX Comparison
LSF vs IFRX Comparison
Compare LSF & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | IFRX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 86.0M |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | LSF | IFRX |
|---|---|---|
| Price | $2.07 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $12.00 | $8.50 |
| AVG Volume (30 Days) | 95.9K | ★ 909.6K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $73,729.00 |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | $1,075.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.07 | $0.71 |
| 52 Week High | $8.96 | $2.77 |
Technical Indicators
Market Signals| Indicator | LSF | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.36 | 42.44 |
| Support Level | $2.13 | $1.00 |
| Resistance Level | $2.52 | $1.12 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 0.65 | 36.09 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.